Living with homozygous familial hypercholesterolemia (HoFH) can feel overwhelming. This rare genetic condition causes dangerously high LDL cholesterol levels from a young age. For children, it means facing the risk of heart disease or stroke far too early in life. However, lomitapide, a medication originally approved for adults in 2012, is showing promising results for kids with HoFH.
The APH-19 clinical trial investigated lomitapide in children aged 5–17. The findings bring hope to families seeking better treatment options.
What is HoFH?
HoFH is an inherited condition that makes it nearly impossible for the body to clear LDL cholesterol—or “bad cholesterol.” Even with standard treatments, like statins or LDL apheresis (a procedure to remove LDL from the blood), many patients still struggle to reach safe cholesterol levels. Left untreated, HoFH leads to early-onset atherosclerosis, where arteries harden and narrow, raising the risk of heart attacks.
Lomitapide works differently. It blocks a protein called microsomal triglyceride transfer protein (MTP), which the body uses to make and transport LDL cholesterol. This unique mechanism gives it an edge, especially for patients whose LDL receptor pathways don’t function well.
The APH-19 Study: What Happened?
Researchers ran a phase 3 clinical trial to test lomitapide in children. The study took place across six countries—Germany, Italy, Spain, Israel, Saudi Arabia, and Tunisia. A total of 43 kids participated.
The trial started with a 6-week preparation period, followed by a 24-week efficacy phase. Kids continued receiving their regular cholesterol-lowering treatments, with lomitapide added to the mix. Younger kids (ages 5–15) started at a 2 mg dose, while teens (ages 16–17) started at 5 mg. Doctors adjusted doses based on how well patients tolerated the medication.
Researchers tracked changes in LDL cholesterol as the primary focus. They also measured total cholesterol, non-HDL cholesterol, VLDL cholesterol, apolipoprotein B, triglycerides, and lipoprotein(a) as secondary outcomes.
The Results: How Well Did It Work?
After 6 months, the results were striking. Lomitapide reduced LDL cholesterol by an average of 54%. This level of reduction is both statistically significant and clinically meaningful.
Other cholesterol markers also showed major improvements:
- Non-HDL cholesterol: Reduced by 54%
- Total cholesterol: Reduced by 50%
- VLDL cholesterol: Reduced by 50%
- Apolipoprotein B: Reduced by 52%
- Triglycerides: Reduced by 50%
- Lipoprotein(a): Reduced by 11% to 24%
These reductions mark an important breakthrough, especially since lomitapide works independently of LDL receptors. This makes it ideal for children with the most severe forms of HoFH.
What About Side Effects?
Like any medication, lomitapide comes with side effects. In this study, most were mild and manageable. Common complaints included gastrointestinal issues like nausea or diarrhea. Some children experienced liver-related effects, such as elevated liver enzymes, but these resolved with dose adjustments.
One child faced a serious liver-related side effect, requiring temporary dose interruptions and reductions. However, the child continued treatment successfully after adjustments. Overall, the safety profile matched what has been seen in adults taking lomitapide.
Why This Matters for Families
HoFH often feels like a race against time, especially for parents watching their kids struggle with high cholesterol despite treatment. Lomitapide offers a new option—one that works differently and delivers significant results.
Unlike invasive procedures like LDL apheresis, lomitapide is taken as a pill, making it easier to fit into daily life. For kids already managing a complex treatment routine, this simplicity matters.
The Bigger Picture
The APH-19 trial shows that lomitapide can lower LDL cholesterol dramatically in children with HoFH. It also underscores the importance of ongoing care. Regular monitoring, a healthy diet, and adherence to all prescribed treatments remain essential.
Lomitapide doesn’t replace existing therapies; it complements them. By adding lomitapide to their routine, children with HoFH can achieve better cholesterol control than ever before.
While lomitapide isn’t a cure, it’s a powerful tool in the fight against HoFH. For many families, it may represent a brighter, healthier future.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is a board-certified endocrinologist based in Montgomery County, Maryland. He is uniquely certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice offers comprehensive, root-cause-focused metabolic and endocrine care, available both virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to optimize long-term health outcomes.
